Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, a Novel HER2-Targeting CAR-Monocyte
Carisma Therapeutics (Nasdaq: CARM) has dosed the first patient in its Phase 1 clinical trial of CT-0525, a novel CAR-Monocyte cellular therapy targeting HER2-overexpressing solid tumors. This marks the first human trial for CAR-Monocytes in a solid tumor setting. Initial data is anticipated by year-end 2024. The trial, open-label in design, aims to evaluate the safety, tolerability, and manufacturing feasibility of CT-0525. It will include patients with advanced or metastatic HER2-positive tumors that have not responded to standard therapies. The trial's design will be featured at the ASCO 2024 Annual Meeting.
- First patient dosed in Phase 1 clinical trial of CT-0525.
- Initial data expected by year-end 2024.
- CT-0525 is the first CAR-Monocyte tested in humans for solid tumors.
- Trial aims to assess safety, tolerability, and manufacturing feasibility.
- Potential for faster manufacturing, higher dosing, and increased potency.
- Collaborations with top cancer centers, including the University of Cincinnati Cancer Center.
- Upcoming presentation at the ASCO 2024 Annual Meeting.
- Only initial data expected by end of 2024, indicating a lengthy trial duration.
- Trial results and efficacy are still uncertain.
- Dependence on successful patient enrollment for trial progression.
- Potential risks associated with open-label trial design.
Insights
The initiation of the Phase 1 clinical trial for CT-0525 by Carisma Therapeutics marks a significant milestone in cancer treatment, particularly for those battling HER2-overexpressing solid tumors. This trial is groundbreaking as it is the first instance of a CAR-Monocyte therapy being evaluated in humans within this context. CAR-M therapies, which involve modifying a patient's immune cells to better attack cancer cells, have shown promise in pre-clinical studies. However, human trials are important for assessing their real-world efficacy and safety.
CT-0525’s potential lies in faster manufacturing, higher dosing and enhanced tumor infiltration, which are improvements over previous CAR-Macrophage programs. For retail investors, it's essential to understand that clinical trials are a lengthy process and while initial data is expected by the end of 2024, the full range of benefits and any potential challenges will only become apparent over time. The success of this trial could pave the way for more advanced and effective cancer treatments, significantly impacting Carisma's market value and positioning in the biopharmaceutical industry.
The development of CT-0525 represents a novel approach to treating HER2-overexpressing solid tumors, which are notoriously difficult to manage with existing therapies. HER2 is a protein that promotes the growth of cancer cells and its overexpression is associated with more aggressive forms of cancer. Traditional treatments for HER2-positive cancers include targeted therapies like trastuzumab, but disease progression remains a significant challenge.
By employing CAR-Monocytes, CT-0525 aims to enhance the body's immune response against these tumors. This approach could potentially address some of the limitations of current HER2-targeting modalities by improving the persistence and potency of the therapeutic cells. For investors, this innovative strategy represents a high-risk, high-reward scenario. If successful, CT-0525 could lead to a new class of cancer therapies and offer substantial returns. However, the inherent uncertainties of early-stage clinical trials should also be considered.
Carisma Therapeutics' announcement about the Phase 1 trial of CT-0525 is a positive signal for investors, highlighting the company's commitment to advancing innovative cancer treatments. The company's focus on solid tumors that overexpress HER2 taps into a large and growing market, given the prevalence of these cancer types. Initial data from the trial is expected by the end of 2024, which provides a timeline for potential developments that investors should watch closely.
From a financial perspective, the successful progression of this trial could lead to increased investor confidence and potentially higher stock valuations. However, it's important to remain cautious as early-stage clinical trials carry significant risks, including the possibilities of unfavorable outcomes or extended timelines. Additionally, the competitive landscape in oncology means that Carisma must continue to demonstrate distinct advantages of CT-0525 over existing and emerging therapies.
CT-0525 is the first CAR-Monocyte to be evaluated in humans in the solid tumor setting
Initial data expected by year-end 2024
"Dosing of the first patient in the CT-0525 Phase 1 trial is a significant step in the development of engineered myeloid cells, marking the first time a CAR-Monocyte is tested in humans in the solid tumor setting," said Eugene P. Kennedy, M.D., Chief Medical Officer of Carisma. "Our pre-clinical data leads us to believe that this next-generation approach of our CAR-M platform has the potential to have a greater impact on patients than our initial CAR-Macrophage program, particularly through faster manufacturing, higher dosing, and increased potency, persistence, and tumor infiltration. We look forward to progressing this trial and expect to report initial data by the end of 2024."
"Patients battling HER2-overexpressing solid tumors face an urgent need for new therapeutic options, as disease progression is a common challenge," commented Davendra Sohal, M.D., M.P.H., Professor of Medicine at the University of Cincinnati Cancer Center. "CT-0525 introduces a differentiated approach to potentially address this shortcoming, offering hope for HER2-positive cancer patients. We are proud to be the first site to treat a patient with CT-0525 and look forward to continuing to collaborate with Carisma and other cancer centers to rapidly enroll patients in the Phase 1 trial."
The Phase 1 clinical trial for CT-0525 is an open-label study designed to assess the safety, tolerability, and manufacturing feasibility of CT-0525. This trial will enroll participants with locally advanced (unresectable) or metastatic solid tumors overexpressing HER2 whose disease has progressed on standard approved therapies. The study will consist of two dose escalation cohorts. Further details of the trial can be found at www.clinicaltrials.gov under NCT identifier: NCT06254807.
Carisma will present a Trial in Progress poster outlining the design of the CT-0525 Phase 1 trial at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, scheduled to take place from May 31 to June 4, 2024, in
About CT-0525
CT-0525 is a first-in-class, ex vivo gene-modified autologous chimeric antigen receptor-monocyte (CAR-Monocyte) cellular therapy intended to treat solid tumors that overexpress human epidermal growth factor receptor 2 (HER2). It is being studied in a multi-center, open label, Phase 1 clinical trial for patients with advanced/metastatic HER2-overexpressing solid tumors that have progressed on available therapies. The CAR-Monocyte approach has the potential to address some of the challenges of treating solid tumors with cell therapies, including tumor infiltration, immunosuppression within the tumor microenvironment, and antigen heterogeneity. CT-0525 has the potential to enable significant dose escalation, enhance tumor infiltration, increase persistence, and reduce manufacturing time compared to macrophage therapy.
About Carisma Therapeutics
Carisma Therapeutics Inc. is a clinical stage biopharmaceutical company focused on utilizing our proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. We have created a comprehensive, differentiated proprietary cell therapy platform focused on engineered macrophages and monocytes, cells that play a crucial role in both the innate and adaptive immune response. Carisma is headquartered in
Cautionary Note on Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to Carisma's business, strategy, future operations, cash runway, the advancement of Carisma's product candidates and product pipeline, and clinical development of Carisma's product candidates, including expectations regarding timing of initiation and results of clinical trials. The words "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "goals," "intend," "may," "might," "outlook," "plan," "project," "potential," "predict," "target," "possible," "will," "would," "could," "should," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. These risks and uncertainties include, but are not limited to, (i) Carisma's ability to obtain, maintain and protect its intellectual property rights related to its product candidates; (ii) Carisma's ability to advance the development of its product candidates under the timelines it anticipates in planned and future clinical trials and with its current financial and human resources; (iii) Carisma's ability to replicate in later clinical trials positive results found in preclinical studies and early-stage clinical trials of its product candidates; (iv) Carisma's ability to realize the anticipated benefits of its research and development programs, strategic partnerships, research and licensing programs and academic and other collaborations; (v) regulatory requirements or developments and Carisma's ability to obtain and maintain necessary approvals from the
For a discussion of these risks and uncertainties, and other important factors, any of which could cause Carisma's actual results to differ from those contained in the forward-looking statements, see the "Risk Factors" set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, its Quarterly Reports on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in Carisma's other recent filings with the Securities and Exchange Commission. Any forward-looking statements that are made in this press release speak as of the date of this press release. Carisma undertakes no obligation to revise the forward-looking statements or to update them to reflect events or circumstances occurring after the date of this press release, whether as a result of new information, future developments or otherwise, except as required by the federal securities laws.
Investors:
Shveta Dighe
Head of Investor Relations
investors@carismatx.com
Media Contact:
Julia Stern
(763) 350-5223
jstern@realchemistry.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/carisma-therapeutics-announces-first-patient-dosed-in-phase-1-clinical-trial-of-ct-0525-a-novel-her2-targeting-car-monocyte-302146805.html
SOURCE Carisma Therapeutics Inc.
FAQ
When was the first patient dosed in Carisma Therapeutics' Phase 1 trial for CT-0525?
What is CT-0525?
When are the initial data for the CT-0525 trial expected?
What is the purpose of Carisma Therapeutics' Phase 1 trial for CT-0525?
What is unique about the CT-0525 trial?
Which medical center is collaborating with Carisma Therapeutics for the CT-0525 trial?
Where can more details about the CT-0525 trial be found?
Where will Carisma Therapeutics present the CT-0525 trial design?
